dibutepinephrine

Aquestive Therapeutics will report Q4 2025 results March 4 and hold investor call March 5, discussing financial performance and pipeline progress including Anaphylm™ development.

Aquestive to present clinical trial data for Anaphylm, an investigational oral anaphylaxis treatment, at 2026 allergy conference, showing promising safety and efficacy results.